SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

(4-NH2)-Exatecan-d5

Cat. No.: HY-145397S

Molecular Formula: $C_{23}H_{16}D_5N_3O_4$

Molecular Weight: 408.46

Target: Topoisomerase; ADC Cytotoxin; Isotope-Labeled Compounds

Pathway: Cell Cycle/DNA Damage; Antibody-drug Conjugate/ADC Related; Others

Storage: -20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 33.33 mg/mL (81.60 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.4482 mL	12.2411 mL	24.4822 mL
	5 mM	0.4896 mL	2.4482 mL	4.8964 mL
	10 mM	0.2448 mL	1.2241 mL	2.4482 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

(4-NH2)-Exatecan-d5 is a deuterated labeled (4-NH2)-Exatecan[1]. (4-NH2)-Exatecan (compound A), a topoisomerase inhibitor, is a derivative of Exatecan. (4-NH2)-Exatecan can be used in the synthesis of antibody-drug conjugates (ADCs)[2].

In Vitro

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

(4-NH2)-Exatecan contains a linker for connecting to a Ligand Unit, wherein the linker is attached in a cleavable manner to the amino residue, characterized by the addition of an amino (NH2) functional group at the 4th position of the parent molecule[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Howard PW, et, al. Compounds and conjugates thereof. US20200306243A1.

[2]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA